The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress

Citation
D. Giuliani et al., The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress, PHARMAC RES, 41(1), 2000, pp. 47-53
Citations number
37
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACOLOGICAL RESEARCH
ISSN journal
10436618 → ACNP
Volume
41
Issue
1
Year of publication
2000
Pages
47 - 53
Database
ISI
SICI code
1043-6618(200001)41:1<47:TCAH2M>2.0.ZU;2-P
Abstract
Experiments were performed on groups of rats after acute and sub-chronic tr eatment (once daily for 9 days) with the cannabinoid agonist HU 210 (25-100 mu g kg(-1), i.p.) as well as 24 h and 7 days after the last drug injectio n. The animals underwent three behavioural tests in novel environments. In the observation cages (Test 1), rat locomotor activity was found to be dose -dependently reduced after acute and sub-chronic treatment at all doses and virtually unchanged during abstinence; grooming was potently inhibited by acute treatment but potentiated by the sub-chronic one at doses of 50 and 1 00 mu g kg(-1), the effect of the higher dose persisting after 24 h and 7 d ays abstinence. Vocalization in animals in response to a tactile stimulus w as highest after HU 210 at 100 mu g kg(-1) in all experimental modes except after 7 days abstinence. In the X-maze (Test 2), sub-chronic HU 210 dose-d ependently enhanced rat natural aversion for open arms, and this behaviour persisted during abstinence after the highest dose. Grooming in the X-maze was completely absent in rats acutely injected with HU 210 but potentiated in those sub-chronically treated or abstinent. In the swimming test (Test 3 ) rats sub-chronically treated at 50 and 100 pg kg(-1) displayed relevant w all-hugging and the same occurred 24 h after last injection. On the whole, our results are indicative of an anxiogenic-like effect of sub-chronic HU 2 10 at high doses and reflect the persistence of enhanced emotional response to novel environments when the treatment is discontinued. (C) 2000 Academi c Press.